Clinical Roundup Combination targeted treatment produces lasting remissions in resistant aggressive DLBCL in phase Ib/II study June 21, 2024Vol.50 No.25
Clinical Roundup Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations June 21, 2024Vol.50 No.25
Clinical Roundup NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death June 21, 2024Vol.50 No.25
Clinical Roundup CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity June 21, 2024Vol.50 No.25
Drugs & Targets FDA approves Keytruda combination for primary advanced or recurrent endometrial carcinoma June 21, 2024Vol.50 No.25
Drugs & Targets EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines June 21, 2024Vol.50 No.25
Drugs & Targets FDA clears IND application for ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers June 21, 2024Vol.50 No.25
NCI NCI faces prospect of an 11% cut in FY25—another setback in a period of tight budgets and sliding paylines June 14, 2024Vol.50 No.24By Matthew Bin Han Ong
Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
